Quality Assurance (QA) is an inevitable part in manufacturing safe drugs, which constantly advances with the developments in technology. Like every other industry, leveraging artificial intelligence (AI), Internet of Things (IoT), and machine learning in quality assurance has contributed to its efficiency and accuracy. With these trends, quality assurance in the pharma space is expected to grow at a CAGR of 12.1 percent to reach a market value of $9.69 billion.
Automation tops as the leading trend in quality assurance. With robotics and artificial intelligence already in place, pharma companies are ensuring lesser human intervention and safer drugs. Automated tests also ensure zero additional costs and a quicker process. Currently, pharma production witnesses a paradigm shift as almost every global pharma leader is shifting to automated quality assurance to enhance continuous manufacturing and productivity.
To put the spotlight on such key developments in the industry, Pharma Tech Outlook illustrates how the pharma sector is leveraging the latest developments in QA. The edition also features thought leadership articles from Matt Southwick, Executive Director Clinical Systems and Analytical Reporting, Amgen [NASDAQ:AMGN], Jon Kallay, Senior Technology and Market Development Manager, Charles River Laboratories, Cathlin Shapiro, Director, Technology Quality Assurance, Parexel, and Federico Piutti, Innovation Manager, Bormioli Pharma, who shed light on various quality assurance approaches for medical and research organizations.
In this edition of Pharma Tech Outlook, we also bring to you the story of some of the top quality assurance solution providers that deliver the best outcomes for their clients. The list comprises GMP Consulting Services for their innovative services that help pharma companies meet federal regulations, and Cromos Pharma for their fully-fledged clinical trials across the entire clinical phase of therapeutics.
Through the following pages, we aim to shine a light on the innovative trends and latest developments in the pharma quality assurance industry. We would like to know your thoughts.
